Related Experiment Video
Updated: May 21, 2026

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
Published on: September 30, 2021
[Clinical efficiency in children treated with intravenous drip infusion of peramivir]
1Department of Pediatrics, Asahikawa Kosei Hospital.
Insights
Peramivir effectively reduced fever in children with influenza, achieving defervescence faster than oseltamivir. This study highlights peramivir as a beneficial treatment option for pediatric influenza cases.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Influenza remains a significant respiratory illness in children.
- Antiviral medications like oseltamivir are commonly used, but new treatment options are continually explored.
- Peramivir, an intravenous neuraminidase inhibitor, offers a potential alternative for influenza treatment.
Purpose of the Study:
- To retrospectively evaluate the clinical effectiveness of peramivir in pediatric patients with influenza.
- To compare the time to defervescence between peramivir and oseltamivir treatment groups.
- To assess the safety profile of peramivir in children.
Main Methods:
- Retrospective analysis of 30 children treated with a single dose of intravenous peramivir (10 mg/kg).
- Comparison with a historical cohort of 30 children treated with oseltamivir (4 mg/kg/day).
- Primary endpoint: time from drug administration to defervescence (body temperature <37.5°C).
Main Results:
- Significantly faster defervescence was observed in the peramivir group compared to the oseltamivir group (p<0.05).
- 80% of patients in the peramivir group achieved defervescence within 24 hours.
- One patient experienced elevated AST and ALT levels as an adverse reaction.
Conclusions:
- Peramivir demonstrated significant clinical effectiveness in treating influenza in children, evidenced by rapid defervescence.
- The study suggests peramivir is a safe and effective option for pediatric influenza.
- Further research may explore peramivir's role in different pediatric populations and influenza strains.
Abstract:
The clinical effect of peramivir was examined retrospectively in 30 children aged 23 days to 8 years; they had been treated with peramivir at our hospital within 48 hours after the onset of influenza from November 2010 to April 2011. Intravenous dripping of peramivir at a dose of 10 mg/kg was performed only once for 15 to 30 minutes. To examine the clinical effect of peramivir, the time from dosing to defervescence (body temperature <37.5 degrees C) was evaluated. To compare the clinical effects of peramivir and oseltamivir, the time required for the defervescence was evaluated in a similar manner in 30 children aged 7 months to 8 years who had been treated for influenza with oseltamivir at a dose of 4 mg/kg/day. The influenza type was type A (n=25) and type B (n=5) in the peramivir group and type A (n=26) and type B (n=4) in the oseltamivir group. In the peramivir group, 5 (16.7%), 16 (53.3%), and 24 (80.0%) patients achieved defervescence within 6, 12, and 24 hours, respectively. In the oseltamivir group, 3 (10.0%) and 6 (20.0%) patients had defervescence within 12 and 24 hours, respectively. The difference between these groups was statistically significant (p<0.05). An increase in the levels of AST and ALT was observed as an adverse reaction in 1 patient. Thus, peramivir was determined to be effective to influenza in children.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
IV Infusion to Oral Dosing: Conversion Methods
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
